Corpus Intelligence IC Memo — SEATTLE CHILDRENS HOSPITAL 2026-04-26 06:55 UTC
IC Memo — SEATTLE CHILDRENS HOSPITAL
Investment Committee Memorandum | WA | 350 beds | Grade B | EBITDA uplift $125.3M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

SEATTLE CHILDRENS HOSPITAL

CCN 503300 | KING, WA | 350 beds | April 26, 2026
EBITDA BridgeData Room
B
Investability

1. Target Overview & Investment Thesis

SEATTLE CHILDRENS HOSPITAL is a 350-bed large academic medical center in KING, WA with $1.70B in net patient revenue and a 5.7% operating margin. The hospital serves a payer mix of 0.6% Medicare, 28.2% Medicaid, and 71.2% commercial.

Thesis: Platform Growth. Our ML models identify $125.3M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 5.7% to 13.1% (+736bps).

Net Revenue HCRIS$1.70B
Current EBITDA COMPUTED$97.2M
Operating Margin COMPUTED5.7%
Occupancy HCRIS78.3%
Revenue / Bed COMPUTED$4.9M
Net-to-Gross HCRIS50.7%
Distress Probability ML44.2%

2. Market Context & Competitive Position

104
WA Hospitals
-10.3%
State Median Margin
26
Comparable Hospitals

WA has 104 Medicare-certified hospitals with a median operating margin of -10.3%. The target's margin of 5.7% places it above the state median. Among 26 size-comparable peers (175-700 beds), the median margin is -11.6%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (175-700), prioritizing same-state peers. 26 hospitals in the comp set.

HospitalStateBedsRevenueMargin
SEATTLE CHILDRENS HOSPITAL (Target)WA350$1.70B5.7%
UNIVERSITY OF WASHINGTON MED CWA592$2.02B-14.4%
SWEDISH MEDICAL CENTERWA603$1.37B-15.2%
TACOMA GENERAL ALLENMORE HOSPIWA374$1.33B5.1%
HARBORVIEW MEDICAL CENTERWA406$1.20B-11.3%
VIRGINIA MASON MEDICAL CENTERWA222$1.11B-23.2%
PROV SACRED HEART MEDICAL CENTWA609$945.8M-24.3%
PROV REGL MED CENTER EVERETTWA548$825.5M-19.6%
PEACEHEALTH SOUTHWEST MEDICAL WA408$813.8M-9.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $125.3M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$35.8M+210bp18mo
Cost to Collect4.5%2.5%$34.0M+200bp12mo
Denial Rate Reduction12.0%6.5%$33.7M+198bp12mo
A/R Days Reduction5200.0%3800.0%$20.7M+122bp9mo
Clean Claim Rate88.0%96.0%$1.1M+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$35.8M
Cost to Collect
$34.0M
Denial Rate Reduction
$33.7M
A/R Days Reduction
$20.7M
Clean Claim Rate
$1.1M
Total EBITDA Uplift$125.3M
Current EBITDA$97.2M
+ RCM Uplift+$125.3M
Pro Forma EBITDA$222.5M
Current Margin5.7%
Pro Forma Margin13.1%
WC Released (1x)$65.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$149.5M$1.89B12.67x66.2%
Base (11x exit)10.0x11.0x$149.5M$2.13B14.26x70.2%
Bull Case9.0x11.0x$134.5M$2.59B19.28x80.7%
Bull (12x exit)9.0x12.0x$134.5M$2.87B21.33x84.4%
Bear Case11.0x10.0x$164.4M$1.22B7.41x49.3%
Bear (11x exit)11.0x11.0x$164.4M$1.39B8.48x53.3%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumElevated Medicaid exposure (28.2%)Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 26 hospitals with 175-700 beds
  • Same-state prioritization (n=27)
  • Comp margins: P25=-15.0% / P50=-11.6% / P75=-5.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.